There are 702 resources available
103P - Prognosis analysis in oligometastatic colorectal cancer with systemic therapy and iodine-125 seed implantation: A retrospective study
Presenter: Dengyao LIU
Session: Poster Display session
104P - A real-world study: Efficacy of the third-line therapy of standard therapy versus rechallenge-chemotherapy in refractory metastatic colorectal cancer
Presenter: Xifeng Xu
Session: Poster Display session
105P - Prognostic value of PIK3CA gene assessment in tissue & plasma in metastatic colorectal cancer (mCRC)
Presenter: Eduardo Terán Brage
Session: Poster Display session
106P - Retrospective analysis of the impact of relative dose intensity on outcomes of colorectal cancer patients treated with 5-FU-based chemotherapy
Presenter: jianfei fu
Session: Poster Display session
107P - Results of metastatic directed therapy (MDT) performed with brachytherapy/interventional radiotherapy in patients with liver metastases from colorectal cancer in repeat oligopersistence clinical scenario: A single institution retrospective analysis
Presenter: Mateusz Bilski
Session: Poster Display session
109P - Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-20
Presenter: Riziero Esposito Abate
Session: Poster Display session
110P - Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study
Presenter: VALENTINO MARTELLI
Session: Poster Display session
111P - Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) al
Presenter: Anna Maria Rachiglio
Session: Poster Display session
112P - The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study
Presenter: Martina Carullo
Session: Poster Display session